The prognostic utility of plasma osteopontin in CAP patients

Publication date: Available online 31 October 2017 Source:Egyptian Journal of Chest Diseases and Tuberculosis Author(s): Ahmed Sh. Mohamed, Ibrahim S. Ibrahim, Ragia S. Sharshar, Amira Y. Abd El-Naby Background: Osteopontin (OPN) is a soluble cytokine glycoprotein widely expressed in many benign and malignant conditions. Purpose of study: was to investigate role of plasma OPN as new biomarker affects prognosis in CAP. Methodology: study was done on 50 subjects divided into 2 groups each 25, CAP (group I), healthy controls (group II). Plasma OPN levels were measured on initial hospitalization and after 3 days of treatment and correlated to severity of CAP by CRP and CURB-65. We concluded that: plasma levels of OPN is increased in pneumonia patients than in healthy controls also before than after 3 days of treatment of CAP. OPN levels significantly correlated with CURB-65 scores but not with CRP levels. Thus, OPN can be used as a novel additional marker, reflecting severity and response to treatment in CAP.
Source: Egyptian Journal of Chest Diseases and Tuberculosis - Category: Respiratory Medicine Source Type: research